Post-Marketing Surveillance of Lenvima in Korean Patients

Eisai logo

Eisai

Status

Completed

Conditions

Differentiated Thyroid Carcinoma (DTC)

Study type

Observational

Funder types

Industry

Identifiers

NCT02764554
E7080-M065-502

Details and patient eligibility

About

The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.

Enrollment

132 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants who meet the following criteria will be eligible for inclusion in the study:

  • Participants with approved indication for lenvatinib in Korea
  • Participants who have written consent for use of personal and medical information for the study purpose

Exclusion criteria

Investigators will refer to approved indications and contraindications regarding exclusion criteria

Trial design

132 participants in 1 patient group

Lenvatinib 4 milligram (mg) and 10 mg capsule
Description:
Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.

Trial contacts and locations

32

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems